Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting

Loading news article.

Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting | WAPE

Eli Lilly To Highlight Phase 3 BRUIN CLL-322 Study Of Jaypirca, Non-Covalent Bruton Tyrosine Kinase Inhibitor, As Part Of Time-Limited Regimen For Patients With Previously Treated Chronic Lymphocytic Leukemia, At EHA Annual Meeting

Article summary

Related companies

Comments —